Although over 50% of the population was injected at least one of the Covid-19 vaccine nose, the US showed signs of breath in front of the Delta transformation due to inadequate in the system.

According to statistics from Mayo Clinic, the leading hospital and medical research network in the US, about 55.7% of the country's population was injected at least one Covid-19 vaccine.

NCOV cases tend to increase near every state.

The number of hospitalizations because Covid-19 also rises again.

Vaccine Covid-19 injection point for California teenagers on July 7 at El Camino College, Torance.

It is worrisome that the number of infections is growing rapidly in a series of states with high vaccination rates like New York, Vermont or California.

All three states have the achievements in the top of the country.

The positive signal is the average number of deaths in the week has decreased by 25%.

According to David Rubin, Director of Policylab Center of Philadelphia Children's Hospital, the risk from the Delta transformation is even more serious in states with low vaccination rates.

Anywhere, the community has a low vaccination rate that is threatened, Jennifer Nuzzo, medical security expert at Johns Hopkins University, warning.

Covid-19 patients were treated in the state of Arkansas, where the vaccine cover was less than 5% of the population.

Scientists and laboratories assessing the discretion of the health system are making the US against the speed of delta spread and the risk of new vaccines.

The sequence of genes is an important anti-epidemic weapon with community health.

Bronwyn Macinnis, the director of genetic supervision of the epidemic at the Broad Institute, noted that the British government soon improved gene sequence capacity to welcome the threat.

In the past 30 days, the US new sequencing gene 2.8% CA positive NCOV records the same period nationwide and shared information for global genetic data warehouse (GisAID).

Data from the US also took 2 weeks to be updated for Gisaid, while in England and Israel were 9 and 12 days respectively.

The above figures show that Britain and Israel do not lose vulnerability to monitor mutations in NCOV despite having a vaccine cover on the percentage of high population similar to the United States.

Challenge lies in the logistics story.

Inside the laboratory sequencing NCOV gene in Cambridge, England.

CDC has partnered with private and university laboratories to expand the scale and accelerate test analysis nationwide.

Arthur Reingold, Head of Epidemiology Department at Berkeley University Community Health School, assessing the US dispersed work for too many medical and laboratory providers.

If you have a NHS model with affiliated labs, you can organize the human resource and ask for a more fluent coordination, he said.

Meanwhile, Bronwyn Macinnis confidently has enough capacity to analyze samples and certainly do not lack testing.

Each state has different regulations on sharing information.

Many regulations are set to protect each individual's privacy.